Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia

Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news